Type 1 interferons potentiate human cd8+ t-cell cytotoxicity through a stat4-and granzyme b-dependent pathway

Diabetes

Volumn 66, Issue 12, 2017, Pages 3061-3071

  Newby, Brittney N ^a   Brusko, Todd M ^a   Zou, Baiming ^b   Atkinson, Mark A ^a   Clare Salzler, Michael ^a   Mathews, Clayton E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GRANZYME B; INTERFERON; RNA; STAT4 PROTEIN; GRANZYME; GZMB PROTEIN, HUMAN; STAT4 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIABETOGENESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PANCREAS ISLET; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; CHILD; DRUG EFFECTS; GENETICS; IMMUNOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GRANZYMES; HUMANS; INTERFERON TYPE I; MALE; PROMOTER REGIONS, GENETIC; STAT4 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 85032216383     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db17-0106     Document Type: Article

References (61)

1. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009;155: 173-181
2. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281: 65-78
3. Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994;43: 505-509
4. Graham KL, Krishnamurthy B, Fynch S, et al. Autoreactive cytotoxic T lymphocytes acquire higher expression of cytotoxic effector markers in the islets of NOD mice after priming in pancreatic lymph nodes. Am J Pathol 2011;178: 2716-2725
5. Nakamura K, Kawasaki E, Imagawa A, et al.; Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: A nationwide survey in Japan. Diabetes Care 2011;34: 2084-2089
6. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF, Type I. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174: 4465-4469
7. Hervas-Stubbs S, Riezu-Boj JI, Gonzalez I, et al. Effects of IFN-a as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol 2010;40: 3389-3402
8. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987;2: 1423-1427
9. Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995;44: 658-664
10. Lundberg M, Krogvold L, Kuric E, Dahl-Jørgensen K, Skog O. Expression of interferon-stimulated genes in insulitic pancreatic islets of patients recently diagnosed with type 1 diabetes. Diabetes 2016;65: 3104-3110
11. Lindenmann J, Burke DC, Isaacs A. Studies on the production, mode of action and properties of interferon. Br J Exp Pathol 1957;38: 551-562
12. Chehadeh W, Weill J, Vantyghem MC, et al. Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: Relationship with coxsackievirus B infection. J Infect Dis 2000;181: 1929-1939
13. Allen JS, Pang K, Skowera A, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 2009;58: 138-145
14. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360: 1646-1654
15. Li Q, Xu B, Michie SA, Rubins KH, Schreriber RD, McDevitt HO. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008; 105: 12439-12444
16. Quah HS, Miranda-Hernandez S, Khoo A, et al. Deficiency in type I interferon signaling prevents the early interferon-induced gene signature in pancreatic islets but not type 1 diabetes in NOD mice. Diabetes 2014;63: 1032-1040
17. Qaisar N, Lin S, Ryan G, et al. A critical role for the type I interferon receptor in virus-induced autoimmune diabetes in rats. Diabetes 2017;66: 145-157
18. Lincez PJ, Shanina I, Horwitz MS. Reduced expression of the MDA5 Gene IFIH1 prevents autoimmune diabetes. Diabetes 2015;64: 2184-2193
19. Pelegrin M, Devedjian JC, Costa C, et al. Evidence from transgenic mice that interferon-beta may be involved in the onset of diabetes mellitus. J Biol Chem 1998; 273: 12332-12340
20. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993;260: 1942-1946
21. Carrero JA, Calderon B, Towfic F, Artyomov MN, Unanue ER. Defining the transcriptional and cellular landscape of type 1 diabetes in the NOD mouse. PLoS One 2013;8: E59701
22. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12: 125-135
23. Kallal LE, Biron CA. Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections. JAK-STAT 2013;2: E23504
24. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5: 375-386
25. Agarwal P, Raghavan A, Nandiwada SL, et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol 2009;183: 1695-1704
26. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF. Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 2009;182: 2786-2794
27. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314: 126-129
28. Babon JA, DeNicola ME, Blodgett DM, et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med 2016; 22: 1482-1487
29. Driver JP, Racine JJ, Ye C, et al. Interferon-g limits diabetogenic CD8(+) T-cell effector responses in type 1 diabetes. Diabetes 2017;66: 710-721
30. Unger WW, Pinkse GG, Mulder-van der Kracht S, et al. Human clonal CD8 autoreactivity to an IGRP islet epitope shared between mice and men. Ann N Y Acad Sci 2007;1103: 192-195
31. Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol 2008;127: 359-365
32. Babad J, Mukherjee G, Follenzi A, et al. Generation of b cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice. Clin Exp Immunol 2015;179: 398-413
33. Lightfoot YL, Chen J, Mathews CE. Role of the mitochondria in immunemediated apoptotic death of the human pancreatic beta cell line betaLox5. PLoS One 2011;6: E20617
34. Brusko TM, Koya RC, Zhu S, et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010;5: E11726
35. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114: 535-546
36. Takaki T, Marron MP, Mathews CE, et al. HLA-A∗0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes. J Immunol 2006;176: 3257-3265
37. Chen J, Grieshaber S, Mathews CE. Methods to assess beta cell death mediated by cytotoxic T lymphocytes. J Vis Exp 2011;52: 2724
38. Gusdon AM, Fernandez-Bueno GA, Wohlgemuth S, Fernandez J, Chen J, Mathews CE. Respiration and substrate transport rates as well as reactive oxygen species production distinguish mitochondria from brain and liver. BMC Biochem 2015;16: 22
39. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149: 274-293
40. Xia CQ, Peng R, Chernatynskaya AV, et al. Increased IFN-a-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: PDCs augment Th1 responses through IFN-a production. J Immunol 2014;193: 1024-1034
41. Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 2009;6: 15-25
42. Gil MP, Ploquin MJ, Watford WT, et al. Regulating type 1 IFN effects in CD8 T cells during viral infections: Changing STAT4 and STAT1 expression for function. Blood 2012;120: 3718-3728
43. Nguyen KB, Watford WT, Salomon R, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002; 297: 2063-2066
44. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012;12: 749-761
45. Glimcher LH, Townsend MJ, Sullivan BM, Lord GM. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 2004;4: 900-911
46. Kaur S, Lal L, Sassano A, et al. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 2007; 282: 1757-1768
47. Pollizzi KN, Powell JD. Regulation of T cells by mTOR: The known knowns and the known unknowns. Trends Immunol 2015;36: 13-20
48. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22: 159-168
49. Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL. Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci 2003;1005: 409-411
50. Yang Z, Chen M, Carter JD, et al. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun 2006; 344: 1017-1022
51. Cho SS, Bacon CM, Sudarshan C, et al. Activation of STAT4 by IL-12 and IFNalpha: Evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 1996;157: 4781-4789
52. Mathelier A, Fornes O, Arenillas DJ, et al. JASPAR 2016: A major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res 2016;44(D1): D110-D115
53. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14: 36-49
54. Hanson RD, Ley TJ. Transcriptional activation of the human cytotoxic serine protease gene CSP-B in T lymphocytes. Mol Cell Biol 1990;10: 5655-5662
55. Haddad P, Wargnier A, Bourge JF, Sasportes M, Paul P. A promoter element of the human serine esterase granzyme B gene controls specific transcription in activated T cells. Eur J Immunol 1993;23: 625-629
56. Hanson RD, Grisolano JL, Ley TJ. Consensus AP-1 and CRE motifs upstream from the human cytotoxic serine protease B (CSP-B/CGL-1) gene synergize to activate transcription. Blood 1993;82: 2749-2757
57. Wargnier A, Legros-Maida S, Bosselut R, et al. Identification of human granzyme B promoter regulatory elements interacting with activated T-cell-specific proteins: Implication of Ikaros and CBF binding sites in promoter activation. Proc Natl Acad Sci U S A 1995;92: 6930-6934
58. Yamamoto K, Miura O, Hirosawa S, Miyasaka N. Binding sequence of STAT4: STAT4 complex recognizes the IFN-gamma activation site (GAS)-like sequence (T/A)TTCC(C/G)GGAA(T/A). Biochem Biophys Res Commun 1997;233: 126-132
59. Funabiki M, Kato H, Miyachi Y, et al. Autoimmune disorders associated with gain of function of the intracellular sensor MDA5. Immunity 2014;40: 199-212
60. Marroqui L, Dos Santos RS, Fløyel T, et al. TYK2, a candidate gene for type 1 diabetes, modulates apoptosis and the innate immune response in human pancreatic b-cells. Diabetes 2015;64: 3808-3817
61. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: Autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009;182: 34-38